Investors

A market pumps are never going to reach

Backed by

The 2M people Luna is built for

The dQ&A sizing model estimates roughly 3.55 million US adults on multiple daily injections or basal-only insulin who use a CGM, excluding pump users. A survey of 583 adults in these groups identified four attitudinal sub-groups. Two of these sub-groups, approximately 2.0 million people, or 56.6% of this group, are the people Luna is built for.1

They are not waiting for a better pump. Only 5% of adults on multiple daily injections and CGM say they are highly or extremely likely to start a pump in the next 12 months.2

Why Luna automates sleep only

Automating insulin has meant wearing a pump around the clock. Luna automates insulin only during the hours when clinical risk is highest and patient burden is lowest. Sleep-only automation isn’t a smaller version of 24/7 automation. It’s a different category, and it reaches a population that existing automation has not.

Where Luna stands with the FDA

Luna is an investigational device and is not yet available. Luna is conducting clinical studies and will eventually go through full FDA review. We are not able to make claims about device performance.

Sources

  1. dQ&A, PWD Survey Results: Luna Patient Segmentation & Jobs To Be Done, January 2026 (fieldwork 13–19 December 2025), slides 5 and 13. Modeled market: 925,000 type 1 MDI + 1,125,000 type 2 MDI + 1,500,000 type 2 basal-only users with CGM = 3.55 million; primary segments approximately 2.0 million (56.6%).
  2. dQ&A, PWD Survey Results: Luna Patient Segmentation & Jobs To Be Done, January 2026 (fieldwork 13–19 December 2025), slide 39; adults with type 1 or type 2 diabetes on multiple daily injections and CGM, n=406. 5% chose highly or extremely likely to start a pump in the next 12 months; 95% did not. This is not a measure of whether they are considering a pump.
A new chapter for overnight

Be the first to know when Luna launches

Luna is not yet available. We’ll let you know when there’s news.

Sign up for updates